U.S. National Institutes of Health  |  www.cancer.gov
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
November 6, 2007 • Volume 4 / Number 29 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF
Notes

Shannon Bell, new director of the Office of Advocacy Relations
Shannon Bell, new director of the Office of Advocacy Relations
Director Named for Advocacy Relations
Shannon Bell has been named as the new director of the Office of Advocacy Relations (OAR), formerly the Office of Liaison Activities. Ms. Bell, whose appointment was effective October 29, previously served as deputy director of NCI's Office of Workforce Development. NCI Director Dr. John E. Niederhuber has relocated OAR in the immediate Office of the Director and appointed Special Assistant Anne Lubenow as his immediate liaison with individuals and organizations who advocate on behalf of cancer research. More information about OAR can be found at http://advocacy.cancer.gov.

Lowy, Schiffman Receive ACS Medals of Honor
NCI's Drs. Douglas R. Lowy and Mark Schiffman recently received the American Cancer Society's (ACS) highest honor, the Medal of Honor. The researchers were recognized for their outstanding contributions to the fight against cancer at a ceremony during the 2007 ACS annual meeting last month.

Dr. Lowy, chief of the Laboratory of Cellular Oncology in NCI's CCR, received the Medal of Honor for Basic Research for his contributions to basic science and research leading to the development of the human papillomavirus (HPV) vaccine, which was carried out in close collaboration with his NCI colleague Dr. John Schiller. Dr. Schiffman, of the Hormonal and Reproductive Epidemiology Branch in DCEG, received the Medal of Honor for Clinical Research for his work in molecular epidemiology relating to HPV.

70 Years of Excellence in Cancer Research

If Memory Serves...

The earliest NCI cancer epidemiology studies in the late 1930s and early 1940s focused on two activities: a survey of radiation protection in hospitals and an evaluation of breast cancer therapy based on records from nine large cancer hospitals. (Read more)

For more information about the birth of NCI, go to http://www.cancer.gov/
aboutnci/ncia.

Niederhuber, Udey Named 2007 AAAS Fellows
Two NCI researchers were elected as AAAS Fellows for outstanding contributions under the Section on Medical Sciences. NCI Director Dr. John E. Niederhuber was elected for his pioneering research on MHC immunology and cancer stems cells, and outstanding leadership of the University of Wisconsin Cancer Center and NCI.

Dr. Mark C. Udey, director of the Dermatology Branch in CCR, was elected for seminal research on the biology of Langerhans cells and the role of E-Cadherin and TGF-beta in their development and localization.

NCI Hosts Public Forums on Biospecimen Resources
NCI is holding a series of public forums about the NCI Best Practices for Biospecimen Resources, which outlines technical, operational, ethical, legal, and policy principles for biospecimen resources. The purpose is to educate and obtain feedback about the NCI Best Practices from a range of perspectives, including those of investigators, physicians, industry representatives, hospital administrators, cancer survivors, patient advocates, and the public. The first forum was held on November 5 in Boston; two more forums will take place on December 3 in Chicago and on January 28, 2008, in Seattle. Attendance is free and open to the public. For more information, go to http://www.nci-bestpractices-forum.com.

Teleconference Focuses on NCI-Frederick
The third fall "Understanding NCI" teleconference will take place on November 8 from 1:00-2:00 p.m., ET, and highlight research conducted at NCI-Frederick. Dr. Craig Reynolds, associate director of NCI-Frederick, will be among those who discuss how their research helps bring new cancer treatments to patients.

Within the U.S., the teleconference can be accessed toll free at 1-800-857-6584; the passcode is FREDERICK. Toll-free playback will be available through December 8 at 1-866-379-4229. To view the series schedule, go to http://advocacy.cancer.gov/activities/teleconferences.